Entegrion to develop blood product for U.S. Navy

08/26/2011 | MedCityNews.com

North Carolina biotech firm Entegrion is set to receive $9.84 million from the Navy for the development of a single blood product that has the potential to save lives on the battlefield. The product will combine two experimental blood products: Resusix, a freeze-dried human plasma designed to serve as an alternative to fresh-frozen plasma, and Stasix, a freeze-dried product based on blood platelets.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA